Since EGFR-induced STAT3 activation has been shown to promote resistance to proteasome inhibitors in MM cells [21], we asked if the STAT3 activation in MM-3D cells contributes to resistance to bortezomib, a proteasome inhibitor commonly used in treating MM patients. The gene discussed is EGFR; the disease is Miyoshi myopathy.